Spots Global Cancer Trial Database for Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC

Official Title: Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial

Study ID: NCT03001596

Conditions

Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0

Interventions

Neoadjuvant Chemoradiotherapy

Neoadjuvant Chemotherapy

Minimally Invasive Esophagectomy

Study Description

Brief Summary: The purpose of this study is to evaluate the outcomes of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy on patients with locally advanced resectable esophageal squamous cell carcinoma(cT3-4aN0-1M0).

Detailed Description: It is a prospective randomized phase III clinical trial sponsored by Shanghai Zhongshan Hospital with other eight hospitals in China participating in. 264 patients with locally advanced resectable esophageal squamous cell carcinoma(cT3-4aN0-1M0) are recruited and randomly assigned into the neoadjuvant chemoradiotherapy group (NCRT group) and the neoadjuvant chemotherapy group (NCT group) according to the proportion of 1:1.The safety,efficacy of protocols and prognosis of patients are compared between the two regimens.